查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953493

抗藥性金黃色葡萄球菌藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類別、給藥途徑、通路、地區及競爭格局分類，2021-2031年）

Methicillin-resistant Staphylococcus Aureus Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗藥性金黃色葡萄球菌(MRSA) 治療市場預計將從 2025 年的 25.6 億美元成長到 2031 年的 36.1 億美元，複合年成長率達到 5.88%。

該市場主要由萬古黴素和Linezolid等藥物組成，這些藥物是專門為對抗對BETA-內醯胺類抗生素抗藥性的葡萄球菌感染疾病而配製的。推動這一成長的主要因素是院內感染的日益增多，尤其是在老年人中，他們更容易出現慢性傷口，並且需要進行侵入性醫療操作。加護病房（ICU）中多重抗藥性病原體的流行也進一步刺激了市場需求，因為那裡迫切需要有效的治療方法。除了廣泛的抗菌藥物管理措施外，這種情況還需要持續的藥物解決方案。

市場概覽
預測期 2027-2031
市場規模：2025年 25.6億美元
市場規模：2031年 36.1億美元
複合年成長率：2026-2031年 5.88%
成長最快的細分市場 脂肽
最大的市場 北美洲

然而，由於缺乏研發新型抗生素的經濟獎勵，市場面臨嚴峻挑戰，導致新藥候選產品線有限。根據國際藥品製造商協會聯合會（IFPMA）2024年的數據，如果沒有額外的投資，未來十年抗生素研發管線中僅有26種治療方法能夠問世，而目前只有6種處於後期研發階段。後期臨床治療方案的匱乏凸顯了製藥公司在將新型耐甲氧西林金黃色葡萄球菌（MRSA）療法商業化方面面臨的巨大困難，尤其是在高昂的研發成本與低投資回報率之間存在巨大差距的情況下。

市場促進因素

強大的臨床研發管線和新型抗生素的核准是全球抗藥性金黃色葡萄球菌(MRSA) 治療市場的主要驅動力，顯著改變了抗藥性革蘭氏陽性病菌感染的治療模式。這項進展包括新一代頭孢菌素類抗生素和其他新型藥物的成功商業化，這些藥物克服了萬古黴素等標準療法的限制。針對金黃色葡萄球菌菌血症 (SAB) 等高風險疾病的新型治療方法的推出，也推動了市場的發展。例如，2025 年 5 月，巴塞爾製藥宣布與 Innoviva Specialty Therapeutics 合作，在美國推出 Zebutera（頭孢吡肟）。該合作計畫包含高達 2.23 億美元的銷售里程碑，證明了治療複雜 MRSA 適應症的商業性可行性。

同時，增加政府對抗生素研究的投入和獎勵對於降低新型治療方法研發風險和維持早期研發管線至關重要。鑑於低商業性回報抑制了私人投資，非營利夥伴關係和政府機構正在提供關鍵的「推動」資金，以幫助生物技術公司推進臨床前候選藥物的研發。例如，2025年1月，CARB-X向Immunartes公司津貼72.9萬美元，用於加速開發一種能夠中和金黃色葡萄球菌免疫逃脫機制的單株抗體。正如美國疾病管制與預防中心（CDC）在2024年11月指出的那樣，這種資金支持對於應對感染率的波動至關重要。雖然上年度醫院獲得性抗甲氧西林金黃色葡萄球菌（MRSA）菌血症下降了16%，但仍需持續投資來應對特定病原體和社區獲得性抗藥性問題。

市場挑戰

全球抗藥性金黃色葡萄球菌（MRSA）治療市場成長的主要障礙在於缺乏研發新型抗生素的經濟獎勵。與能夠產生穩定收入的慢性病治療藥物不同，新型MRSA抗生素通常僅短期使用，且需遵守嚴格的藥物管理計劃，這些計劃透過限制用藥來維持療效。這種結構性的市場失靈導致銷售量與臨床價值脫節，使得製藥公司難以收回高昂的研發成本或獲得足夠的投資回報。因此，產業巨頭紛紛退出該領域，將重擔轉移到小規模的生技公司身上，而這些公司往往缺乏足夠的財力來應對昂貴的監管核准流程。

這種財務不穩定直接限制了治療抗藥性菌株所需的創新治療方法的商業性化應用。據抗菌藥物抗藥性產業聯盟（AMR Industry Alliance）稱，其成員公司預計到2024年每年將在抗生素研發方面投入約20億美元，但業內人士認為這筆金額不足以維持強大的新藥研發管線。這種投資不足限制了新型耐甲氧西林金黃色葡萄球菌（MRSA）療法的推出，進而限制了整個市場的獲利能力。

市場趨勢

全球抗藥性金黃色葡萄球菌(MRSA) 治療市場正因新型非抗生素療法的出現而重塑，這些療法利用精準工具繞過傳統的抗藥性機制。與常會破壞宿主微生物群的頻譜抗生素不同，噬菌體和溶素等先進治療方法特異性靶向細菌毒力因子，從而根除多重抗藥性菌株。在該領域，Faqiam Therapeutics 公司於 2024 年 11 月獲得 FDA核准，進行一項評估其專有特異性噬菌體療法的 II 期臨床試驗，這是一項重大進展。這種向高特異性生物製藥的轉變，為那些對標準藥物療法無效的複雜生物膜相關感染疾病患者提供了至關重要的替代方案。

同時，人工智慧（AI）正日益融入抗生素藥物研發領域，加速從龐大的化合物庫中篩選出有前景的候選藥物，從而解決該領域普遍存在的高失敗率和高成本問題。深度學習演算法使研究人員能夠快速預測分子對金黃色葡萄球菌的療效和毒性，並從以往難以獲得的微生物資源中發現新的化學骨架。作為對這項技術投資的一個象徵性例證，亥姆霍茲感染疾病研究中心於2024年11月宣布，已向一個歐洲聯盟授予1100萬歐元的津貼，用於開發一個針對包括耐甲氧西林金黃色葡萄球菌（MRSA）在內的重點病原體的抗生素研發人工智慧平台。這體現了數據驅動方法對於重振藥物研發生態系統至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球抗藥性金黃色葡萄球菌藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類別（Oxazolidinone、脂肽類、頭孢菌素類、四環黴素、葉酸拮抗劑類、其他）
    • 依給藥途徑（口服、注射給藥）
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美抗藥性金黃色葡萄球菌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲抗藥性金黃色葡萄球菌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區抗藥性金黃色葡萄球菌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲抗藥性金黃色葡萄球菌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲抗藥性金黃色葡萄球菌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球抗藥性金黃色葡萄球菌藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Melinta Therapeutics LLC
  • Basilea Pharmaceutica Ltd.
  • Theravance Biopharma
  • Wockhardt Limited
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23814

The Global Methicillin-resistant Staphylococcus Aureus Drugs Market is projected to expand from USD 2.56 Billion in 2025 to USD 3.61 Billion by 2031, achieving a CAGR of 5.88%. This market largely consists of pharmaceutical agents, including vancomycin and linezolid, which are specifically formulated to combat staphylococcal infections resistant to beta-lactam antibiotics. A key driver of this growth is the increasing prevalence of hospital-acquired infections, particularly among the aging population, who are more prone to chronic wounds and require invasive medical procedures. Furthermore, the demand is intensified by the urgent need for effective therapies in intensive care units, where multidrug-resistant pathogens persist, requiring continuous pharmaceutical solutions separate from broader antibiotic stewardship efforts.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.56 Billion
Market Size 2031USD 3.61 Billion
CAGR 2026-20315.88%
Fastest Growing SegmentLipopeptides
Largest MarketNorth America

However, the market faces a substantial challenge due to the lack of economic incentives for developing new antimicrobials, resulting in a restricted pipeline of novel candidates. Data from the International Federation of Pharmaceutical Manufacturers and Associations in 2024 indicates that, without additional investment, the antibiotic pipeline will yield only 26 treatments over the next decade, with merely six currently in late-stage development. This scarcity of late-stage clinical options highlights the significant difficulties pharmaceutical companies encounter in commercializing new MRSA drugs, particularly given the disparity between high research costs and low returns on investment.

Market Driver

The robust clinical pipeline and the approval of novel antibiotic classes serve as major catalysts for the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, significantly altering the treatment landscape for resistant gram-positive infections. This progress involves the successful commercialization of advanced-generation cephalosporins and other novel agents that address the limitations of standard therapies like vancomycin. Significant momentum is evident with the introduction of new therapies for high-risk conditions such as Staphylococcus aureus bacteremia (SAB). For example, Basilea Pharmaceutica announced in May 2025 the US launch of Zevtera (ceftobiprole medocaril), a partnership with Innoviva Specialty Therapeutics that includes potential sales milestones reaching USD 223 million, validating the commercial viability of treating complex MRSA indications.

Concurrently, increased government funding and incentives for antimicrobial research are essential for sustaining the early-stage pipeline by de-risking the development of new treatments. Recognizing the market failure where low commercial returns deter private investment, non-profit partnerships and government bodies provide crucial "push" funding to help biotech firms advance preclinical candidates. For instance, CARB-X awarded US$729,000 to Immunartes in January 2025 to accelerate a monoclonal antibody designed to neutralize S. aureus immune-evasion mechanisms. This financial support is vital to counter fluctuating infection rates, as noted by the CDC in November 2024; although hospital-onset MRSA bacteremia decreased by 16% the prior year, continued investment is necessary to address niche and community-associated resistance.

Market Challenge

A primary barrier inhibiting the growth of the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is the lack of economic incentives for developing new antimicrobials. Unlike medications for chronic diseases that provide steady revenue, novel MRSA antibiotics are usually prescribed for short durations and are subject to strict stewardship programs that limit their use to preserve efficacy. This structural market failure disconnects sales volume from clinical value, making it extremely difficult for pharmaceutical companies to recover high research and development costs or achieve a viable return on investment. Consequently, major industry players have exited the sector, shifting the burden to smaller biotechnology firms that often lack the capital to navigate the expensive regulatory approval process.

This financial instability directly restricts the commercial availability of innovative therapies needed to treat resistant strains. According to the AMR Industry Alliance, member companies reported a collective annual investment of approximately USD 2 billion in antimicrobial research and development in 2024, a figure the industry describes as insufficient to maintain a robust pipeline of new medicines. This stagnation in investment limits the introduction of new MRSA drugs, thereby constraining the overall revenue potential of the market.

Market Trends

The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is being reshaped by the emergence of novel non-antibiotic therapeutic modalities that utilize precision tools to bypass traditional resistance mechanisms. Unlike broad-spectrum antibiotics that often disrupt the host microbiome, advanced options such as bacteriophages and lysins specifically target bacterial virulence factors to eradicate multidrug-resistant strains. A significant development in this area occurred in November 2024, when Phaxiam Therapeutics received FDA approval to launch a Phase II clinical trial evaluating its specialized phage therapy. This shift toward high-specificity biologics offers a critical alternative for patients with complex, biofilm-associated infections that do not respond to standard pharmacotherapy.

Simultaneously, the integration of Artificial Intelligence into antimicrobial drug discovery is accelerating the identification of potent candidates from vast chemical libraries, addressing the high attrition rates and costs typical of the sector. Deep learning algorithms enable researchers to rapidly predict molecular efficacy and toxicity against Staphylococcus aureus, uncovering novel chemical scaffolds from previously inaccessible microbial sources. Highlighting the investment in this technology, the Helmholtz Centre for Infection Research reported in November 2024 that a European consortium received a EUR 11 million grant to develop an AI-based platform for discovering antibiotics for priority pathogens, including MRSA, representing a data-driven approach vital for revitalizing the discovery ecosystem.

Key Market Players

  • Melinta Therapeutics LLC
  • Basilea Pharmaceutica Ltd.
  • Theravance Biopharma
  • Wockhardt Limited
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.

Report Scope

In this report, the Global Methicillin-resistant Staphylococcus Aureus Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Drug Class

  • Oxazolidinones
  • Lipopeptides
  • Cephalosporin
  • Tetracycline
  • Folate Antagonist
  • Other

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Route of Administration

  • Oral Administration
  • Parenteral Administration

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methicillin-resistant Staphylococcus Aureus Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market.

Available Customizations:

Global Methicillin-resistant Staphylococcus Aureus Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, Folate Antagonist, Other)
    • 5.2.2. By Route of Administration (Oral Administration, Parenteral Administration)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Methicillin-resistant Staphylococcus Aureus Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Methicillin-resistant Staphylococcus Aureus Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Melinta Therapeutics LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Basilea Pharmaceutica Ltd.
  • 15.3. Theravance Biopharma
  • 15.4. Wockhardt Limited
  • 15.5. Paratek Pharmaceuticals, Inc.
  • 15.6. Seres Therapeutics Inc.
  • 15.7. Merck & Co. Inc.
  • 15.8. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer